119 related articles for article (PubMed ID: 38388236)
1. Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase Ⅳ clinical trial.
Yin Q; Zheng Y; Ying Z; Li J; Jiang Y; Bao W; Dou Y; Pu Y; Lei J; Yang H; Jiang R; Deng Y; Zhao Z; Pu J; Yang J; Li Y; Xu M; Cai W; Che Y; Shi L
Vaccine; 2024 Mar; 42(8):1973-1979. PubMed ID: 38388236
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
Chu K; Li Y; Yu D; Song Y; Liu S; Xue F; Shan Y; Meng W; Pan H
Vaccine; 2023 May; 41(22):3467-3471. PubMed ID: 37127526
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months.
Feng G; Jiang D; Han W; Xie Z; Jiang Z; Huang L; Wang J; Zhang W; Xu L; Tan J; You W; Cui G; Li C; Wang Y
Int J Infect Dis; 2023 May; 130():20-27. PubMed ID: 36682682
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.
Jiang R; Liu X; Sun X; Wang J; Huang Z; Li C; Li Z; Zhou J; Pu Y; Ying Z; Yin Q; Zhao Z; Zhang L; Lei J; Bao W; Jiang Y; Dou Y; Li J; Yang H; Cai W; Deng Y; Che Y; Shi L; Sun M
Vaccine; 2021 Mar; 39(9):1463-1471. PubMed ID: 33487470
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
[TBL] [Abstract][Full Text] [Related]
8. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
[No Abstract] [Full Text] [Related]
9. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
Sun G; Wang G; Zhong H
Inflammopharmacology; 2024 Apr; 32(2):1025-1038. PubMed ID: 38308795
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
11. Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China.
Tang X; Xiao Y; Deng X; Zhou Y; Chen H; Yan R; Zhu Y; Wang S; Wang H; Zhu X; Luo L; Liu Y; Yin Z; Zhang G; Chen Z; Jiang J; Yang X; He H
Lancet Reg Health West Pac; 2023 May; 34():100725. PubMed ID: 37283972
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial.
Sun X; Xu Y; Tang F; Xiao Y; Wang Z; Wang B; Zhu X; Yang X; Chen H
Front Immunol; 2022; 13():905634. PubMed ID: 35958596
[TBL] [Abstract][Full Text] [Related]
13. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).
Okada K; Miyazaki C; Kino Y; Ozaki T; Hirose M; Ueda K
J Infect Dis; 2013 Jul; 208(2):275-83. PubMed ID: 23568174
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
[TBL] [Abstract][Full Text] [Related]
15. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM
Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464
[TBL] [Abstract][Full Text] [Related]
17. Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial.
Zheng Y; Ying Z; Zou Y; Zhu T; Qian D; Han W; Jiang Y; Jiang Z; Li X; Wang J; Lei J; Xu L; Jiang D; Li C; Liu X
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214712
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
19. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months.
Feng G; Shao M; Wang J; Huang L; Tan J; Jiang Z; You W; Li Y; Yang Y; Li J; Wang Y
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400106
[TBL] [Abstract][Full Text] [Related]
20. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
